Effects of Omeprazole on Recurrent Clostridioides difficile Infection Caused by ST81 Strains and Their Potential Mechanisms

Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0022123. doi: 10.1128/aac.00221-23. Epub 2023 May 24.

Abstract

Clostridioides difficile infection (CDI) is associated with high recurrence rates that have substantial effects on patients' quality of life. To investigate the risk factors and potential mechanisms contributing to recurrent CDI (rCDI), a total of 243 cases were enrolled in this study. The history of omeprazole (OME) medication and ST81 strain infection were considered the two independent risks with the highest odds ratios in rCDI. In the presence of OME, we detected concentration-dependent increases in the MIC values of fluoroquinolone antibiotics against ST81 strains. Mechanically, OME facilitated ST81 strain sporulation and spore germination by blocking the pathway of purine metabolism and also promoted an increase in cell motility and toxin production by turning the flagellar switch to the ON state. In conclusion, OME affects several biological processes during C difficile growth, which have fundamental impacts on the development of rCDI caused by ST81 strains. Programmed OME administration and stringent surveillance of the emerging ST81 genotype are matters of considerable urgency and significance in rCDI prevention.

Keywords: Clostridioides difficile infection; ST81; omeprazole; recurrence; regulatory mechanism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides difficile* / genetics
  • Clostridium Infections* / prevention & control
  • Fluoroquinolones / pharmacology
  • Humans
  • Omeprazole / pharmacology
  • Omeprazole / therapeutic use
  • Quality of Life
  • Recurrence

Substances

  • Omeprazole
  • Fluoroquinolones
  • Anti-Bacterial Agents